Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Advanced glycation end products: role in pathology of diabetic cardiomyopathy.

Bodiga VL, Eda SR, Bodiga S.

Heart Fail Rev. 2014 Jan;19(1):49-63. doi: 10.1007/s10741-013-9374-y. Review.

PMID:
23404649
2.

AGE, RAGE, and ROS in diabetic nephropathy.

Tan AL, Forbes JM, Cooper ME.

Semin Nephrol. 2007 Mar;27(2):130-43. Review.

PMID:
17418682
3.

Role of advanced glycation end products (AGEs) and oxidative stress in diabetic retinopathy.

Yamagishi S, Ueda S, Matsui T, Nakamura K, Okuda S.

Curr Pharm Des. 2008;14(10):962-8. Review.

PMID:
18473846
4.

Role of advanced glycation end products in diabetic neuropathy.

Sugimoto K, Yasujima M, Yagihashi S.

Curr Pharm Des. 2008;14(10):953-61. Review.

PMID:
18473845
5.

Advanced glycation end-products (AGEs) and heart failure: pathophysiology and clinical implications.

Hartog JW, Voors AA, Bakker SJ, Smit AJ, van Veldhuisen DJ.

Eur J Heart Fail. 2007 Dec;9(12):1146-55. Review.

6.

Role of advanced glycation end products and their receptors in development of diabetic neuropathy.

Wada R, Yagihashi S.

Ann N Y Acad Sci. 2005 Jun;1043:598-604. Review.

PMID:
16037282
7.

Advanced glycation end products and receptor-oxidative stress system in diabetic vascular complications.

Yamagishi S.

Ther Apher Dial. 2009 Dec;13(6):534-9. doi: 10.1111/j.1744-9987.2009.00775.x. Review.

PMID:
19954478
8.

Diabetic cardiomyopathy: understanding the molecular and cellular basis to progress in diagnosis and treatment.

Falc√£o-Pires I, Leite-Moreira AF.

Heart Fail Rev. 2012 May;17(3):325-44. doi: 10.1007/s10741-011-9257-z. Review.

PMID:
21626163
9.

Role of advanced glycation end products (AGEs) and receptor for AGEs (RAGE) in vascular damage in diabetes.

Yamagishi S.

Exp Gerontol. 2011 Apr;46(4):217-24. doi: 10.1016/j.exger.2010.11.007. Review.

PMID:
21111800
10.
11.

Advanced glycation end products and diabetic nephropathy.

Thomas MC, Forbes JM, Cooper ME.

Am J Ther. 2005 Nov-Dec;12(6):562-72. Review.

PMID:
16280650
12.

Importance of advanced glycation end products in diabetes-associated cardiovascular and renal disease.

Cooper ME.

Am J Hypertens. 2004 Dec;17(12 Pt 2):31S-38S. Review.

PMID:
15607433
13.
14.

Advanced glycation end products and diabetic foot disease.

Huijberts MS, Schaper NC, Schalkwijk CG.

Diabetes Metab Res Rev. 2008 May-Jun;24 Suppl 1:S19-24. doi: 10.1002/dmrr.861. Review.

PMID:
18442180
15.

Crosstalk between the renin-angiotensin system and the advance glycation end product axis in the heart: role of the cardiac fibroblast.

Yamazaki KG, Gonzalez E, Zambon AC.

J Cardiovasc Transl Res. 2012 Dec;5(6):805-13. doi: 10.1007/s12265-012-9405-4. Review.

PMID:
23054657
16.

The role of AGEs in cardiovascular disease.

Jandeleit-Dahm K, Cooper ME.

Curr Pharm Des. 2008;14(10):979-86. Review.

PMID:
18473849
17.

The receptor for advanced glycation end-products has a central role in mediating the effects of advanced glycation end-products on the development of vascular disease in diabetes mellitus.

Hori O, Yan SD, Ogawa S, Kuwabara K, Matsumoto M, Stern D, Schmidt AM.

Nephrol Dial Transplant. 1996;11 Suppl 5:13-6. Review.

PMID:
9044300
18.

AGEs, rather than hyperglycemia, are responsible for microvascular complications in diabetes: a "glycoxidation-centric" point of view.

Chilelli NC, Burlina S, Lapolla A.

Nutr Metab Cardiovasc Dis. 2013 Oct;23(10):913-9. doi: 10.1016/j.numecd.2013.04.004. Review.

PMID:
23786818
19.

Agents that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: a novel therapeutic strategy for diabetic vascular complications.

Yamagishi S, Nakamura K, Matsui T, Ueda S, Fukami K, Okuda S.

Expert Opin Investig Drugs. 2008 Jul;17(7):983-96. doi: 10.1517/13543784.17.7.983 . Review.

PMID:
18549336
20.

Receptor for advanced glycation end products (RAGE): a novel therapeutic target for diabetic vascular complication.

Yamagishi S, Nakamura K, Matsui T, Noda Y, Imaizumi T.

Curr Pharm Des. 2008;14(5):487-95. Review.

PMID:
18289075
Items per page

Supplemental Content

Support Center